நூலகத்திடம் கேளுங்கள்

A multi-centre Phase I clinical trial reported that a CRISPR-based therapy improved hearing in six children with **genetic deafness caused by mutations in the OTOF gene** (which is associated with auditory neuropathy). After treatment, the children **regained near-normal hearing**, indicating that gene-editing delivered to the inner ear can restore functional hearing in at least some cases of inherited deafness [1]. Key points from the report: - **Who was treated:** Six children with **OTOF mutations** linked to genetic deafness [1]. - **Trial stage:** **Phase I** (early-stage, focused primarily on safety while also observing early signs of benefit) [1]. - **Outcome:** Participants showed **substantial hearing recovery**, described as **near-normal hearing** after therapy [1]. - **Why it matters:** It’s a notable clinical milestone suggesting **CRISPR gene editing** can be translated beyond lab studies into **meaningful sensory restoration** in humans, at least for specific single-gene forms of hearing loss [1]. If you want, tell me what you’d like to focus on—e.g., *how the therapy is delivered to the ear, what “near-normal” likely means clinically (audiometry/ABR), safety considerations in Phase I, or what this implies for other genetic causes of deafness*—and I’ll expand on that.